ResearcherCandel Therapeutics (United States)Active in the last 2 years

W. Garrett Nichols

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 8 November 2026

Matched on OpenAlex author ID A5113800241. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2024: 1 paper

Papers 1

Neoadjuvant CAN-2409 plus Prodrug in Combination with Standard of Care Chemoradiation for Borderline Resectable Pancreatic Adenocarcinoma Co-author DOI 10.21203/rs.3.rs-5183420/v1 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Paul Peter Tak · 1 shared paper, 2024 · strength 0.22
- Paper Neoadjuvant CAN-2409 plus Prodrug in Combination with Standard of Care Chemoradiation for Borderline Resectable Pancrea… DOI 10.21203/rs.3.rs-5183420/v1 ↗
Mark Bloomston · 1 shared paper, 2024 · strength 0.22
- Paper Neoadjuvant CAN-2409 plus Prodrug in Combination with Standard of Care Chemoradiation for Borderline Resectable Pancrea… DOI 10.21203/rs.3.rs-5183420/v1 ↗
Fidel David Huitzil Melendez · 1 shared paper, 2024 · strength 0.22
- Paper Neoadjuvant CAN-2409 plus Prodrug in Combination with Standard of Care Chemoradiation for Borderline Resectable Pancrea… DOI 10.21203/rs.3.rs-5183420/v1 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.